Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Diluted Average) (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $62.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 15.28% to $62.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.0 million through Dec 2025, up 15.28% year-over-year, with the annual reading at $62.0 million for FY2025, 15.28% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $62.0 million at Janux Therapeutics, roughly flat from $61.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $62.0 million in Q4 2025, with the low at $5.6 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $45.5 million, with a median of $44.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) soared 640.57% in 2022, then rose 0.85% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $23.5 million in 2021, then soared by 76.24% to $41.5 million in 2022, then rose by 6.14% to $44.0 million in 2023, then rose by 22.12% to $53.8 million in 2024, then grew by 15.28% to $62.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $62.0 million, $61.9 million, and $61.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.